secwatch / observer
8-K filed June 1, 2026, 4:22 PM ET ticker ESPR CIK 0001434868
other material confidence high sentiment neutral materiality 0.50

Esperion shareholders approve 7M-share increase to 2022 equity incentive plan

Esperion Therapeutics, Inc.

item 5.02item 5.07item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001628280-26-039518
form_type
8-K
ticker
ESPR
cik
0001434868
company_name
Esperion Therapeutics, Inc.
filed_at
2026-06-01T20:22:15+00:00
discovered_at
2026-06-01T20:23:00.247923+00:00
generated_at
2026-06-01T20:35:07.666843+00:00
sec_items
["5.02", "5.07", "9.01"]
event_type
other_material
sentiment
neutral
materiality_score
0.5
calibrated_materiality_score
0.5
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001628280-26-039518
json_url
https://secwatch.observer/filing/0001628280-26-039518.json
markdown_url
https://secwatch.observer/filing/0001628280-26-039518.md
text_url
https://secwatch.observer/filing/0001628280-26-039518.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/0001628280-26-039518-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1434868/000162828026039518/espr-20260528.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

0910c3811492c95f2d31303f1f3817387db9fd7a

Esperion Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent auditor at the 2026-05-28 meeting.

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

2536072c08ba76ad3f635334fd9ca34398baa79a

Esperion Therapeutics, Inc. shareholders approved Amendment to 2022 Equity Incentive Plan to increase shares by 7,000,000 at the 2026-05-28 meeting.

The Company’s stockholders approved Proposal 4. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 108,150,213 22,489,001 454,840 46,114,802

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

37f9ebbee0d9198d1ed11c68483cb682f191bd93

Esperion Therapeutics, Inc. shareholders approved Election of two Class I directors: J. Martin Carroll and Sheldon L. Koenig at the 2026-05-28 meeting.

The Company’s stockholders approved the Class I director nominees recommended for election in Proposal 1 at the Annual Meeting. The Company’s stockholders voted for Class I directors as follows: Class I Director Nominee For Withhold Broker Non-Votes J. Martin Carroll 105,082,565 26,011,489 46,114,802 Sheldon L. Koenig 109,672,941 21,421,113 46,114,802

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

c699dd06e484bbd03024093ebf299b6d17c92d2f

Esperion Therapeutics, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-05-28 meeting.

The Company’s stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 95,650,226 34,866,033 577,795 46,114,802

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

Comparable filings

CRM

Salesforce shareholders approve 34M share equity plan increase, extend term to 2036, all directors re-elected

Salesforce, Inc. June 1, 2026, 4:43 PM ET other_material Items 5.07, 5.02, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

Comparable filing

Advisory vote to approve the fiscal 2026 compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 493,864,228 117,716,717 668,510 102,463,325

Filing page SEC filing

BRANDYWINE OPERATING PARTNERSHIP, L.P.

Brandywine extends revolver maturity to Dec 2026; shareholders OK 5M share increase for LTIP

BRANDYWINE OPERATING PARTNERSHIP, L.P. June 1, 2026, 4:30 PM ET other_material Items 1.01, 2.03, 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

Comparable filing

PROPOSAL 2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for calendar year 2026. Votes For Votes Against Abstentions 134,853,955 7,100,190 646,621

Filing page SEC filing

SIRI

Sirius XM shareholders approve 7.2M share increase in 2024 equity plan, elect directors

SIRIUS XM HOLDINGS INC. June 1, 2026, 4:28 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

Comparable filing

Election of Directors The holders of our common stock elected the persons listed below as Class I directors. Votes Cast For Votes Withheld Broker Non-Votes Eddy W. Hartenstein 229,472,971 4,921,855 51,448,019 Kristina M. Salen 231,643,217 2,751,609 51,448,019 Jennifer C. Witz 230,660,585 3,734,241 51,448,019 The holders of our common stock elected the persons listed below as Class II directors. Votes Cast For Votes Withheld Broker Non-Votes Evan D. Malone 230,881,893 3,512,933 51,448,019 Jonelle Procope 210,894,725 23,500,101 51,448,019 Anjali Sud 213,150,753 21,244,073 51,448,019

Filing page SEC filing

LUV

Southwest shareholders approve amended equity plan with 4.75M share increase; all directors elected

SOUTHWEST AIRLINES CO May 20, 2024, 7:59 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

Comparable filing

3. Proposal 3 – Approval of the Southwest Airlines Co. Amended and Restated 2007 Equity Incentive Plan: VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 408,346,613 28,870,401 1,635,532 90,613,942

Filing page SEC filing

Regulus Therapeutics Inc.

Regulus shareholders approve 2019 Equity Plan amendment adding 9.5M shares

Regulus Therapeutics Inc. May 17, 2024, 7:59 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

Comparable filing

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

Filing page SEC filing

OSUR

OraSure shareholders approve 3M share increase in stock plan, charter amendment limiting officer liability

ORASURE TECHNOLOGIES INC May 17, 2024, 7:59 PM ET other_material Items 5.02, 5.03, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

Comparable filing

ITEM 1 . Election of two Class III Directors for Terms Ending in 2027. NAME Votes For Votes Against Abstentions Broker Non-Votes Nancy J. Gagliano, M.D. 57,243,711 4,832,639 46,575 5,007,157 Lelio Marmora 57,332,773 4,732,865 57,287 5,007,157

Filing page SEC filing

Nemaura Medical Inc.

Shareholders approve reverse stock split authorization at ratio of 1:10 to 1:150

Nemaura Medical Inc. May 17, 2024, 7:59 PM ET other_material Items 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

Comparable filing

On May 9, 2024, the Shareholders of Nemaura Medical Inc. (the “Company”) approved by written consent to authorize amendments to the Articles of Incorporation of the Company (the “Articles”) to effect a reverse stock split of the common stock, par value $0.001 per share, of the Company (the “Common Stock”) ranging in ratio between 1-for-10 and 1-for-150, with one share of Common Stock being issued for a range of between each 10 and 150 shares of Common Stock issued and outstanding, with such final ratio to be determined by the Board following approval thereof by the shareholders of the Company, with any fractional shares of Common Stock resulting therefrom being rounded up to the nearest whole share of Common Stock (the “Reverse Split”), and to amend the Articles to effect the Reverse Split.

Filing page SEC filing

INTEVAC INC

Stockholders approve share increases for ESPP and equity incentive plan at 2024 annual meeting

INTEVAC INC May 17, 2024, 7:59 PM ET other_material Items 5.02, 5.07

same fact type: shareholder_vote same SEC item: 5.02, 5.07 same event type: other_material similar materiality

This filing

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

Comparable filing

Proposal 5: Advisory Approval of Named Executive Officer Compensation Intevac’s stockholders approved, on a non-binding, advisory basis, the compensation of Intevac’s named executive officers.

Filing page SEC filing

Source: SEC EDGAR
accession 0001628280-26-039518
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.